User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

1335

Interactions with Platform & by Email *

INTERACTIONS

240

Unique # Participated *

PARTICIPANTS

53

Responses Validated *

VALIDATIONS

13

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers .....I-2
Data Interpretation & Reporting Level .....I-2
  
   Quantitative Techniques & Analytics .....I-3
Product Definitions and Scope of Study .....I-3
  
   Paclitaxel - Leading from the Front.....II-1
US Market - Magnificently Outdistancing Others.....II-1
Cancer Blockbusters - Facing the Brunt.....II-1
A Sunrise Opportunity.....II-1
1$100
   BMS’ Reign Comes to an End.....II-2
Exploring New Avenues .....II-2
Falling Prices - Boon for The Customers, Bane for The Companies .....II-2
1$100
   All the Strangle for Peanuts?.....II-3
Factors Affecting the Market.....II-3
Paclitaxel Versus Abraxane.....II-3
2$200
   Bulk Paclitaxel - Great Future Ahead.....II-5
Competitive Scenario.....II-5
Cancer Generics - A Time for Optimism.....II-5
1$100
   The US Piazza.....II-6
1$100
   Chemical Properties.....II-7
Sourcing.....II-7
1$100
   From Natural Sources.....II-8
Yew Trees.....II-8
From Semi-Synthesis Process.....II-8
Mechanism of Action.....II-8
1$100
   History of Paclitaxel and its Discovery as an Anti-Cancer Agent .....II-91$100
   China Wins Laurels for Supply of Natural Paclitaxel.....II-10
Hazelnut Trees Emerge as the Alternate Source of Paclitaxel.....II-10
1$100
   Taxol - The Uncrowned Leader .....II-11
Paclitaxel - Concerns.....II-11
Abraxane and Tocosol: Set to Ride the Market Duel?.....II-11
1$100
   Many Faces (Phases) of Paclitaxel - The Variants.....II-12
Taxotere - A Potential Competitor to Paclitaxel.....II-12
1$100
   Angiotech Unfurls New Dimensions for Paclitaxel.....II-13
Clinical Research Favors Paclitaxel for Breast Cancer Treatment.....II-13
American BioScience’ Nab Technology Unveils Higher Tissue Penetration
  Potential.....II-13
1$100
   Naturol Develops Unique Extraction Technology for Producing Paclitaxel from Canadian
  Yew .....II-14
Ivax Corp.’s Xorane Revolutionizes the Delivery of Paclitaxel .....II-14
1$100
   Dabur Launches Cancer Drug......II-15
Dabur Introduces Nanoxel......II-15
Nippon Introduces Paclitaxel Injection NK......II-15
1$100
   Sonus to Merge with OncoGenex ......II-16
Acusphere Signs Licensing Deal with Cephalon ......II-16
Sonus Terminates TOCOSOL Paclitaxel Development Program ......II-16
Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel ......II-16
Pliva Lachema Receives ANDA for Paclitaxel Injection ......II-16
1$100
   Cell Therapeutics Receives EMEA Acceptance ......II-17
Abraxis Wins Approval for ABRAXANE in Korea ......II-17
Boston Scientific Obtains Approval for TAXUS Liberte from Health Canada ......II-17
Cell Therapeutics Renames Xyotax as Opaxio......II-17
Hospira Takes Over Mayne Pharma ......II-17
Protherics to Acquire MacroMed ......II-17
1$100
   Abraxis Acquires Arizona Production Facility ......II-18
Indena Inks Worldwide License Agreement with Spectrum Pharma ......II-18
Bioxel Bags Major Paclitaxel Order ......II-18
Bioxel Enters into Supply Agreement......II-18
1$100
   Bioxel Bags Paclitaxel Supply Contract ......II-19
Indena Establishes New Plant to Produce Synthetic Paclitaxel ......II-19
Abraxis Selects Korean Green Cross to Market ABRAXANE ......II-19
Abraxis Grants License to Biocon for Marketing ABRAXANE ......II-19
Bioxel Registers Docetaxel with US FDA ......II-19
1$100
   Bayer Quashes TOCOSOL Paclitaxel License with Sonus ......II-20
Abraxis’ ABRAXANE Convinces European CHMP ......II-20
Abraxis Receives Approval for ABRAXANE in Australia ......II-20
Eurocor Receives CE Mark......II-20
SuperGen Divests Certain Drugs to Intas ......II-20
Abraxis Plans Separation of Oncology Business......II-20
1$100
   Teva Acquires IVAX.....II-21
Mayne to Acquire Nipent and SurfaceSafe Product Rights in North America.....II-21
Athersys Expands Research Collaboration with Bristol-Myers Squibb.....II-21
1$100
   American Pharmaceutical Partners and American BioScience Combine to Create Abraxis
  BioScience.....II-22
Bioxel Increases its Presence in Europe.....II-22
Xechem Resolves Paclitaxel Antitrust Lawsuit with Bristol-Myers Squibb.....II-22
Angiotech Acquires American Medical Instruments.....II-22
Paxis Signs Supply Agreement for Europe and the United States.....II-22
Angiotech to Take Over Quill Medical.....II-22
1$100
   Bioxel and Cook Enters Supply Agreement for Paclitaxel.....II-23
Angiotech Acquires Lifespan Vascular Graft Business.....II-23
Bristol-Myers Extends Agreement with Ambit.....II-23
Angiotech Takes Over Afmedica.....II-23
Bristol-Myers Squibb Gets European Approval for Paclitaxel .....II-23
1$100
   Angiotech Signs Exclusive License Agreement with CABG Medical.....II-24
Conor Medsystems Acquires the Assets of Phytogen Life Sciences.....II-24
Sonus Pharmaceuticals and Schering Sign Licensing Agreement......II-24
Sonus’ Tocosol Wins FDA’s ODD .....II-24
1$100
   ABI’s Abraxane Wins FDA Approval.....II-25
SuperGen’s Paclitaxel Injection Accorded ANDA Status from the USFDA.....II-25
Ivax Signs Agreement with Mayne.....II-25
Integrated Bio Pharma Acquires Hauser CRO.....II-25
Mayne Gearing up to Fight it Alone with Proprietary Paclitaxel.....II-25
Bioxel Inks a Paclitaxel Supply Deal with CTI.....II-25
DFB Pharmaceuticals Takes Over Phyton.....II-25
1$100
   NaPro Divests Paclitaxel Business to Faulding.....II-26
Bioxel-Aerojet’s Large-Scale Paclitaxel Purification Process Gets FDA’s Nod .....II-26
Ivax Earns Expanded Approval for Paxene from the European Commission.....II-26
Sonus Obtains Third Patent for the Composition of Tocosol Paclitaxel .....II-26
Bioxel Forays into the European Market.....II-26
1$100
   Xechem Pockets Additional Patents for Second Generation Paclitaxel .....II-27
Dabur Pharma Initiates Phase IIb Trial for Nanoparticle Delivery Systems.....II-27
Acusphere Inc. Completes Phase 1 Trial for AI-850.....II-27
Tisorex Changes Name to Paxis Pharmaceuticals.....II-27
1$100
   Abraxis BioScience, Inc. (USA).....II-28
Bioxel Pharma Inc. (Canada).....II-28
Bristol-Myers Squibb Co. (USA).....II-28
Hospira, Inc. (USA) ......II-28
1$100
   Indena S.p.A. (Italy).....II-29
OncoGenex Pharmaceuticals, Inc. (USA)......II-29
Teva Pharmaceuticals USA, Inc. (USA) ......II-29
1$100
   Xechem International Inc. (USA).....II-30
1$100
   Table 1: World Recent Past, Current & Future Analysis for Bulk Paclitaxel by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding Graph/Chart)......II-311$300
   Table 2: World Long-term Projections for Bulk Paclitaxel by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)......II-321$300
   Table 3: World Recent Past, Current & Future Analysis for Bulk Paclitaxel by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)......II-331$300
   Table 4: World Long-term Projections for Bulk Paclitaxel by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)......II-341$300
   Table 5: World 10-Year Perspective for Bulk Paclitaxel by Geographic Region – Percentage Breakdown by Volume Sales for US and Rest of World Markets for Years 2003, 2008, & 2012......II-35

Table 6: World 10-Year Perspective for Bulk Paclitaxel by Geographic Region – Percentage Breakdown by Dollar Sales for US and Rest of World Markets for Years 2003, 2008, & 2012......II-35
1$300
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Rising Demand for Paclitaxel.....III-1
Alarming Growth of Breast Cancer.....III-1
Clinical Research Favors Paclitaxel for Breast Cancer Treatment.....III-1
1$75
   Paclitaxel – An Important Element.....III-2
Corporate Talk.....III-2
Drug-Eluting Stents - Marching Ahead.....III-2
Strategic Corporate Developments .....III-2
5$375
   Key Players.....III-73$225
   B. Market Analytics.....III-10
Table 7: US Recent Past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-10

Table 8: US Long-term Projections for Bulk Paclitaxel Market with Annual Sales in Kilograms for Years 2011 through 2015.(includes corresponding Graph/Chart).....III-10
1$150
   Table 9: US Recent Past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-11

Table 10: US Long-term Projections for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)......III-11
1$150
   A. Market Analysis.....III-12
Current and Future Analysis.....III-12
Europe......III-12
European Market Overview.....III-12
European Market Battling Cost-Containment Woes.....III-12
1$75
   Efforts to Improve the Scenario and their Effect on Paclitaxel Market.....III-13
China......III-13
Chinese Government Strategizing to Save Paclitaxel Reserves.....III-13
Product Launches/Developments......III-13
1$75
   Strategic Corporate Development .....III-146$450
   Key Players.....III-202$150
   B. Market Analytics.....III-22
Table 11: Rest of World Recent Past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in Kilograms for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-22

Table 12: Rest of World Long-term Projections for Bulk Paclitaxel with Annual Sales in Kilograms for Years 2011 through 2015 (includes corresponding Graph/Chart)......III-22
1$150
   Table 13: Rest of World Recent Past, Current & Future Analysis for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-23

Table 14: Rest of World Long-term Projections for Bulk Paclitaxel Market with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)......III-23
1$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com